Yiliang Wei

Yiliang Wei has a diverse work experience in the field of biology and drug discovery. They started their career as an Undergraduate Research Assistant at Beijing Normal University in 2008, where they worked until 2010. In 2009, they joined the National Institute of Biological Sciences as an Undergraduate Research Assistant for a year.

Yiliang then joined Michigan State University in 2010, where they worked as a Graduate Assistant until 2016. During this time, they conducted research on the transcriptional regulation of the insulin receptor gene in Drosophila and identified the genome-wide occupancy of Drosophila retinoblastoma proteins.

In 2016, Yiliang became a Postdoctoral Fellow at Cold Spring Harbor Laboratory. They focused on performing in vivo CRISPR-Cas9 screenings in an AML CDX model in mice, identifying synthetic lethality in AML, and conducting CRISPR-Cas9 screenings in human cancer cell lines.

In 2020, Yiliang joined Syros Pharmaceuticals as a Scientist II in Oncology Drug Discovery. They established screening SOPs, performed routine screenings, and conducted CRISPR engineering and RNAi experiments in mammalian cancer cell lines. They held this position until 2022 when they were promoted to Senior Scientist, and they continued their work until 2023.

Currently, Yiliang works at Treeline Biosciences as a Senior Scientist in Drug Discovery Biology, starting in 2023.

Yiliang Wei completed a Bachelor of Science degree in Biological Sciences from Beijing Normal University in 2010. From 2010 to 2016, they pursued and successfully received a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from Michigan State University.